KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib

PLoS Medicine

Volumn 2, Issue , 2005, Pages 0057-0061

  Pao, William ^a   Wang, Theresa Y ^a   Riely, Gregory J ^a   Miller, Vincent A ^a   Pan, Qiulu ^a   Ladanyi, Marc ^a   Zakowski, Maureen F ^a   Heelan, Robert T ^a   Kris, Mark G ^a   Varmus, Harold E ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; PHOSPHOTRANSFERASE INHIBITOR; PROTEIN; PROTEIN KRAS; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; QUINAZOLINE DERIVATIVE;

ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; GENE MUTATION; HUMAN; HUMAN TISSUE; LUNG ADENOCARCINOMA; PREDICTION; ADENOCARCINOMA; DECISION MAKING; DRUG RESISTANCE; GENETICS; LUNG NON SMALL CELL CANCER; LUNG TUMOR; ONCOGENE RAS; TREATMENT OUTCOME;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; DECISION MAKING; DRUG RESISTANCE, NEOPLASM; GENES, RAS; HUMANS; LUNG NEOPLASMS; QUINAZOLINES; TREATMENT OUTCOME;

EID: 15744372810     PISSN: 15491277     EISSN: None     Source Type: Journal    
DOI: 10.1371/journal.pmed.0020017     Document Type: Article

References (13)

1. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, et al. (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350: 2129-2139.
2. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, et al. (2004) EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 304: 1497-1500.
3. Pao W, Miller V, Zakowski M, Doherty J, Politi K, et al. (2004) EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 101: 13306-13311.
4. Stephens P, Hunter C, BignellG, Edkins S, Davies H, et al. (2004) Lung cancer: Intragenic ERBB2 kinase mutations in tumours. Nature 431: 525-526.
5. Rodenhuis S, Slebos RJC, Boot AJM, Evers SG, Mooi WJ, et al. (1988) Incidence and possible clinical significance of K-ras oncogene activation in adenocarcinoma of the human lung. Cancer Res 48: 5738-5741.
6. Suzuki Y, Orita M, Shiraishi M, Hayashi K, Sekiya T (1990) Detection of ras gene mutations in human lung cancers by single-strand conformation polymorphism analysis of polymerase chain reaction products. Oncogene 5: 1037-1043.
7. Rodenhuis S, Slebos RJ (1990) The ras oncogenes in human lung cancer. Amer Rev Resp Dis 142: S27-S30.
8. Gazdar A, Shigematsu H, Herz J, Minna J (2004) Mutations and addiction to EGFR: The Achilles 'heal' of lung cancers? Trends Mol Med 10: 481-486.
9. Ahrendt SA, Decker PA, Alawi EA, Zhu YR, Sanchez-Cespedes M, et al. (2001) Cigarette smoking is strongly associated with mutation of the K-ras gene in patients with primary adenocarcinoma of the lung. Cancer 92: 1525-1530.
10. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, et al. (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92: 205-216.
11. Sordella R, Bell DW, Haber DA, Settleman J (2004) Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 305: 1163-1167.
12. Altman DG, Machin D, Bryant TN, Gardner MJ, editors (2000) Statistics with confidence, 2nd ed. London: BMJ Books. 240 p.
13. Rusch VW, Reuter VE, Kris MG, Kurie J, Miller WH, et al. (1992) Ras oncogene point mutation: An infrequent event in bronchioloalveolar cancer. J Thor Cardiovasc Surg 104: 1465-1469.